Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.antiviral.2020.104996 http://scihub22266oqcxt.onion/10.1016/j.antiviral.2020.104996 33309540!7726485!33309540     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Antiviral+Res 2021 ; 185 (ä): 104996 Nephropedia Template TP {{tp|p=33309540|t=2021. Antiviral activity against Middle East Respiratory Syndrome coronavirus by Montelukast, an anti-asthma drug |pdf=|usr=}}{{33309540}} gab.com Text Antiviral activity against Middle East Respiratory Syndrome coronavirus by Montelukast, an anti-asthma drug JO: Antiviral Res http://www.kidney.de/pget.php?&tw=1&pmid=33309540 #FOAvip Middle East Respiratory Syndrome (MERS) is a respiratory disease caused by a coronavirus (MERS-CoV). Since its emergence in 2012, nosocomial amplifications have led to its high epidemic potential and mortality rate of 34.5%. To date, there is an unmet need for vaccines and specific therapeutics for this disease. Available treatments are either supportive medications in use for other diseases or those lacking specificity requiring higher doses. The viral infection mode is initiated by the attachment of the viral spike glycoprotein to the human Dipeptidyl Peptidase IV (DPP4). Our attempts to screen antivirals against MERS led us to identify montelukast sodium hydrate (MSH), an FDA-approved anti-asthma drug, as an agent attenuating MERS-CoV infection. We showed that MSH directly binds to MERS-CoV-Receptor-Binding Domain (RBD) and inhibits its molecular interaction with DPP4 in a dose-dependent manner. Our cell-based inhibition assays using MERS pseudovirions demonstrated that viral infection was significantly inhibited by MSH and was further validated using infectious MERS-CoV culture. Thus, we propose MSH as a potential candidate for therapeutic developments against MERS-CoV infections. Twit Text FOAVip Antiviral activity against Middle East Respiratory Syndrome coronavirus by Montelukast, an anti-asthma drug ????Antiviral Res http://www.kidney.de/pget.php?&tw=1&pmid=33309540 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33309540 #FOAvip English Wikipedia <ref>{{Cite pmid|33309540}}</ref> Antiviral activity against Middle East Respiratory Syndrome coronavirus by Montelukast, an anti-asthma drug #MMPMID33309540 Gan HJ; Harikishore A; Lee J; Jeon S; Rajan S; Chen MW; Neo JL; Kim S; Yoon HS Antiviral Res 2021[Jan]; 185 (ä): 104996 PMID33309540show ga Middle East Respiratory Syndrome (MERS) is a respiratory disease caused by a coronavirus (MERS-CoV). Since its emergence in 2012, nosocomial amplifications have led to its high epidemic potential and mortality rate of 34.5%. To date, there is an unmet need for vaccines and specific therapeutics for this disease. Available treatments are either supportive medications in use for other diseases or those lacking specificity requiring higher doses. The viral infection mode is initiated by the attachment of the viral spike glycoprotein to the human Dipeptidyl Peptidase IV (DPP4). Our attempts to screen antivirals against MERS led us to identify montelukast sodium hydrate (MSH), an FDA-approved anti-asthma drug, as an agent attenuating MERS-CoV infection. We showed that MSH directly binds to MERS-CoV-Receptor-Binding Domain (RBD) and inhibits its molecular interaction with DPP4 in a dose-dependent manner. Our cell-based inhibition assays using MERS pseudovirions demonstrated that viral infection was significantly inhibited by MSH and was further validated using infectious MERS-CoV culture. Thus, we propose MSH as a potential candidate for therapeutic developments against MERS-CoV infections. |Acetates/*pharmacology[MESH] |Animals[MESH] |Anti-Asthmatic Agents/pharmacology[MESH] |Antiviral Agents/*pharmacology[MESH] |Carrier Proteins/drug effects[MESH] |Chlorocebus aethiops[MESH] |Coronavirus Infections/drug therapy[MESH] |Cyclopropanes/*pharmacology[MESH] |Cytochrome P-450 CYP1A2 Inducers/pharmacology[MESH] |Dipeptidyl Peptidase 4/genetics/metabolism[MESH] |Drug Repositioning[MESH] |HEK293 Cells[MESH] |Humans[MESH] |Leukotriene Antagonists/pharmacology[MESH] |Middle East Respiratory Syndrome Coronavirus/*drug effects[MESH] |Quinolines/*pharmacology[MESH] |Receptors, Virus/genetics/metabolism[MESH] |Spike Glycoprotein, Coronavirus/metabolism[MESH] |Sulfides/*pharmacology[MESH] |Vero Cells[MESH]Antiviral activity against Middle East Respiratory Syndrome coronaviru(epmc).pdf DeepDyve Pubget Overpricing